Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death - PubMed (original) (raw)
doi: 10.4161/auto.19009. Epub 2012 Feb 24.
Mickaël Michaud, Abdul Qader Sukkurwala, Sandy Adjemian, Yuting Ma, Shensi Shen, Oliver Kepp, Laurie Menger, Erika Vacchelli, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer
Affiliations
- PMID: 22361584
- DOI: 10.4161/auto.19009
Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
Isabelle Martins et al. Autophagy. 2012 Mar.
Abstract
One particular strategy to render anticancer therapies efficient consists of converting the patient's own tumor cells into therapeutic vaccines, via the induction of immunogenic cell death (ICD). One of the hallmarks of ICD dwells in the active release of ATP by cells committed to undergo, but not yet having succumbed to, apoptosis. We observed that the knockdown of essential autophagy-related genes (ATG3, ATG5, ATG7 and BECN1) abolishes the pre-apoptotic secretion of ATP by several human and murine cancer cell lines undergoing ICD. Accordingly, autophagy-competent, but not autophagy-deficient, tumor cells treated with ICD inducers in vitro could induce a tumor-specific immune response in vivo. Cancer cell lines stably depleted of ATG5 or ATG7 normally generate tumors in vivo, and such autophagy-deficient neoplasms, upon systemic treatment with ICD inducers, exhibit the same levels of apoptosis (as monitored by nuclear shrinkage and caspase-3 activation) and necrosis (as determined by following the kinetics of HMGB1 release) as their autophagy-proficient counterparts. However, autophagy-incompetent cancers fail to release ATP, to recruit immune effectors into the tumor bed and to respond to chemotherapy in conditions in which autophagy-competent tumors do so. The intratumoral administration of ecto-ATPase inhibitors increases extracellular ATP concentrations, re-establishes the therapy-induced recruitment of dendritic cells and T cells into the tumor bed, and restores the chemotherapeutic response of autophagy-deficient cancers. Altogether, these results suggest that autophagy-incompetent tumor cells escape from chemotherapy-induced (and perhaps natural?) immunosurveillance because they are unable to release ATP.
Similar articles
- Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Michaud M, et al. Science. 2011 Dec 16;334(6062):1573-7. doi: 10.1126/science.1208347. Science. 2011. PMID: 22174255 - ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, Agostinis P. Garg AD, et al. Autophagy. 2013 Sep;9(9):1292-307. doi: 10.4161/auto.25399. Epub 2013 Jun 19. Autophagy. 2013. PMID: 23800749 - Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity.
Lotze MT, Buchser WJ, Liang X. Lotze MT, et al. Autophagy. 2012 Aug;8(8):1264-6. doi: 10.4161/auto.20752. Epub 2012 Jun 4. Autophagy. 2012. PMID: 22660171 - Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Kepp O, et al. Apoptosis. 2009 Apr;14(4):364-75. doi: 10.1007/s10495-008-0303-9. Apoptosis. 2009. PMID: 19145485 Review. - Molecular characteristics of immunogenic cancer cell death.
Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Tesniere A, et al. Cell Death Differ. 2008 Jan;15(1):3-12. doi: 10.1038/sj.cdd.4402269. Epub 2007 Nov 16. Cell Death Differ. 2008. PMID: 18007663 Review.
Cited by
- Emerging role of immunogenic cell death in cancer immunotherapy.
Arimoto KI, Miyauchi S, Liu M, Zhang DE. Arimoto KI, et al. Front Immunol. 2024 May 10;15:1390263. doi: 10.3389/fimmu.2024.1390263. eCollection 2024. Front Immunol. 2024. PMID: 38799433 Free PMC article. Review. - Emerging dimensions of autophagy in melanoma.
Pangilinan C, Klionsky DJ, Liang C. Pangilinan C, et al. Autophagy. 2024 Aug;20(8):1700-1711. doi: 10.1080/15548627.2024.2330261. Epub 2024 Mar 21. Autophagy. 2024. PMID: 38497492 Review. - Shifting the paradigm: engaging multicellular networks for cancer therapy.
Hu J, Ascierto P, Cesano A, Herrmann V, Marincola FM. Hu J, et al. J Transl Med. 2024 Mar 12;22(1):270. doi: 10.1186/s12967-024-05043-8. J Transl Med. 2024. PMID: 38475820 Free PMC article. Review. - Molecular determinants of immunogenic cell death elicited by radiation therapy.
Galassi C, Klapp V, Yamazaki T, Galluzzi L. Galassi C, et al. Immunol Rev. 2024 Jan;321(1):20-32. doi: 10.1111/imr.13271. Epub 2023 Sep 7. Immunol Rev. 2024. PMID: 37679959 Free PMC article. Review. - Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies to Promote the Anti-Tumor Immune Response.
Pelka S, Guha C. Pelka S, et al. Biomedicines. 2023 Aug 10;11(8):2245. doi: 10.3390/biomedicines11082245. Biomedicines. 2023. PMID: 37626741 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials